EUVIMEDEUVIMED entdecken
Crossref

SGLT2 inhibitors for the treatment of pulmonary hypertension; new trends

Mohammad Memarian, Rahimeh Eskandarian

Journal of Renal Injury Prevention · 27.04.2025 · 14 (3) · e38409

DOI: 10.34172/jrip.2025.38409 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Renal Injury Prevention, online erschienen am 27.04.2025. Verfasst von Mohammad Memarian und 1 weiteren Autor:innen. Die Arbeit wurde bisher 2-mal zitiert (Crossref).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The landscape of pulmonary hypertension (PAH) treatment is evolving, with SGLT2 inhibitors being recognized as a potential fourth treatment pathway alongside traditional therapies. Their incorporation into treatment strategies for PAH could represent a significant shift in management approaches.

Zitieren

APA

Memarian, M., & Eskandarian, R. (2025). SGLT2 inhibitors for the treatment of pulmonary hypertension; new trends. Journal of Renal Injury Prevention, 14(3), e38409. https://doi.org/10.34172/jrip.2025.38409

Vancouver

Memarian M, Eskandarian R. SGLT2 inhibitors for the treatment of pulmonary hypertension; new trends. Journal of Renal Injury Prevention. 2025;14(3):e38409. doi:10.34172/jrip.2025.38409

BibTeX
@article{Memarian2025,
  author = {Memarian, Mohammad and Eskandarian, Rahimeh},
  title = {SGLT2 inhibitors for the treatment of pulmonary hypertension; new trends},
  journal = {Journal of Renal Injury Prevention},
  year = {2025},
  volume = {14},
  number = {3},
  pages = {e38409},
  doi = {10.34172/jrip.2025.38409}
}
Kostenlos starten →